Therapeutic Update on Actinic Keratosis
July 2014 | Volume 13 | Issue 7 | Feature | 785 | Copyright © 2014
Deborah S. Sarnoff MD FAAD FACP
No abstract available
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Actinic keratosis (AK) is a premalignant skin condition typically seen almost exclusively in Caucasians, due to their fair skin. AKs develop on chronically sun-exposed areas such as the face, the dorsum of the hands and forearms, upper chest, and the scalp of bald men. While AKs have been described as “precancers,” histologic and molecular features suggest that they exist in a continuum with invasive squamous cell carcinoma. A small percentage of AKs eventually evolve into invasive squamous cell carcinoma; it is for this reason that eradication of lesions is warranted. The estimated frequency of conversion is from 0.1% to as high as 16%,1 but the likelihood of a particular AK progressing to invasive squamous cell carcinoma with metastatic potential is impossible to predict.
There are many treatment options that have similar efficacy. Destructive therapies such as cryosurgery or electrodessication and curettage are directed at specific clinical lesions. Medical therapies, also known as field-directed therapies, use a pharmacologic approach to destroy both the clinical AKs and the subclinical lesions in the surrounding skin.
When selecting a treatment, the dermatologist must keep in mind that the expectations of “baby boomers” may be different from patients of prior generations. Patients today desire eradication of lesions with rapid wound healing and minimal cosmetic alteration.2
Local destructive therapies are most commonly used when treating a small number of lesions. Field-directed medical therapy is warranted when there are many AKs and extensive photodamage. It has been shown that the combination of targeted destructive therapy with field-directed therapy has a synergistic effect.
I. Local Destructive Therapies1. Cryosurgery
Cryosurgery is the most popular first-line treatment for AK. Liquid nitrogen, at a temperature of -196°, freezes the lesions and the atypical cells are destroyed. Since melanocytes in the skin are also sensitive to cold, cryosurgery can leave macules of hypopigmentation.2. Curettage and Electrodessication
The use of curettage and electrodessication is a surgical technique involving the use of a curette to physically scrape atypical cells and electrocautery to obtain hemostasis and thermally destroy additional atypical cells. The technique is most useful for spot treating lesions, especially those that are hypertrophic.
II. Field-Directed Medical Therapies
There are currently 5 topical medications commonly used for the treatment of AKs:1. 5-fluorouracil (5FU) – (Efudex®, Flouroplex,® and Carac®)
5FU is an antimetabolite drug used in chemotherapy for treatment of colorectal cancer.3 It is taken up by cells as if it were uracil. Its active metabolites are subsequently incorporated into DNA and RNA, disrupting replication, and causing cell destruction. Common side effects include erythema, crusting and burning. Formulations include a 5% cream or solution, a 2% solution, a 1% cream or solution, and a micronized 0.5% cream.2. Imiquimod – (Aldara®, Zyclara™)
Imiquimod is an immunomodulator that has been shown to stimulate immune function by inducing cytokine expression, interferon-α (IFN-α),4 interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Formulations include 5% cream (Aldara®), 3.75% cream (Zyclara®), and 3.75% solution.3. Diclofenac gel – (Solaraze™)
Diclofenac sodium 3% gel is a nonsteroidal anti-inflammatory drug (NSAID). It is a non-selective cyclooxygenase (COX) inhibitor which also exhibits anti-tumor effects, given that COX-2 has been implicated in keratinocyte proliferation.5,6 Diclofenac has also been shown to induce apoptosis via death receptor signaling.7 A lengthy, 3-month treatment course is typically required to eradicate AKs.4. Ingenol mebutate gel – (Picato®)
Ingenol mebutate is a naturally occurring active substance found in the sap of the plant, Euphorbia peplus.8 The quick action is thought to arise from both direct cytotoxicity leading to cell death and activation of a neutrophil-mediated inflammatory response.9 The short duration of therapy is a plus, but the brisk inflammatory reaction can be a drawback. This agent is typically used for only 3 consecutive days (0.015%) for face and scalp, and 2 consecutive days (0.05%) for the trunk and extremities.